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ABSTRAK 
TAJUK:  PERBANDINGAN KEBERKESANAN BAGI INFUSI “REMIFENTANIL” 
SAHAJA DENGAN INFUSI  “REMIFENTANIL” DITAMBAH  “MIDAZOLAM” 
SEMASA PEMBEDAHAN  “ TENKCHOFF” DALAM RAWATAN PENGAWASAN 
ANESTHESIA BAGI PESAKIT KEGAGALAN BUAH PINGGANG  
Pengenalan:  
Ubat “Remifentanil” ialah sejenis ubat tahan sakit,  digunakan untuk tujuan  meningkatkan 
keberkesanan  pembiusan setempat bagi mengurangkan ketidakselesaan dan kesakitan 
pesakit semasa rawatan pengawasan anesthesia. Tetapi, dos remifentanil yang diperlukan, 
interaksi dengan ubat penenang seperti “midazolam”, dan profil keselamatan terutamanya 
dalam pesakit kegagalan buah pinggang yang menjalani pembedahan ‘tenckhoff ’ belum 
dikenal pasti lagi. Oleh itu, kajian ini telah dijalankan  untuk menentukan dos infusi yang 
sesuai  untuk ‘remifentanil’  sahaja  atau apabila ditambah dengan ‘midazolam’, dan dalam 
masa yang sama untuk menilai keselamatan dan keberkesanan ‘remifentanil’ dalam 
pembedahan tenckhoff. 
 
Kaedah:  
58 pesakit yang dijadualkan untuk operasi  ‘tenckhoff’  semasa rawatan pengawasan  
anesthesia telah mengambil bahagian dalam kajian ini setelah kajian ini mendapat 
kelulusan oleh Jawatankuasa Penyelidikan dan Etika, Pusat Pengajian Sains Perubatan, 
Universiti Sains Malaysia, Kampus Kesihatan Kelantan. Walau bagaimanapun, 3 pesakit 
terpaksa dikeluarkan dari kajian ini  kerana bertukar kepada  pembiusam am penuh.  
Pesakit- pesakit dibahagikan secara rawak kepada dua Kumpulan: (1)  ‘remifentanil’  
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bermula pada dos 0.5ng /ml  , dan plasebo ditambahkan, (2) ‘remifentanil’  bermula pada 
0.5ng /ml  dan  ‘midazolam’ 0.02 mg/kg ditambahkan . Ubat bius setempat 
‘levobupivacaine’ dengan dos maksimal dos 2 mg /kg kemudian dibenarkan untuk disuntik. 
Penilaian lisan tahap kesakitan, ketidakselesaan dan ketenangan dijalankan.  Tahap 
kesakitan, ketidakselesaan dan ketenangan seterusnya dinilai setiap 5 minit. Saturasi 
oksigen pesakit, kadar pernafasan dan dengutan jantung akan diawasi pada setiap 5 minit. 
Dos ‘ Remifentanil’ ditmabah secara berperingkat 0.1ng / ml daripada kadar permulaan  
untuk mengawal ketidakselesaan atau kesakitan pesakit. Selepas operasi , pesakit akan 
dinilai  kesan sampingan ubat tahan sakit seperti loya, muntah dan gatal  
 
Keputusan: 
 Pada masa  suntikan bius setempat, lebih banyak pesakit dalam kumpulan ‘remifentanil + 
plasebo’  mengalami sakit yang paling teruk (78.6%) dan ketidakselesaan yang  paling 
teruk (46.4%)  apabila dibandingkan dengan Kumpulan ‘midazolam + remifetanil’ (29.6% 
dan 11.1%, masing-masing).  Dos ‘Remifentanil’ ‘mean ±SD’  bagi operasi ini ialah 1.57 ± 
0.11 ng/ml ( kumpulan remifentanil + plasebo)  bagi dan 0.92 ± 0.11 ng/ml ( kumpulan 
remifentanil + midazolam). Kumpulan ‘midazolam + remifentanil’ mencapai skor 
kesakitan < 4 dalam masa (minit)   lebih cepat berbanding kumpulan plasebo (9.78 dan  
22.36 minit masing masing ; p < 0.05) Secara amnya, kumpulan pesakit-pesakit 
‘ Midazolam + remifentanil’ mempunyai lebih banyak  komplikasi  semasa operasi . 7 
pesakit (25.9%) dalam Kumpulan ‘remifentanil  + midazolam’  dan 2 pesakit (7.1%) dalam 
Kumpulan ‘remifentanil  
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sahaja’ mengalami  kekurangan kadar penafasan dalam tempoh yang singkat (< 8 
nafas/min). Di sisi lain, Kumpulan pesakit- pesakit  ‘Remifetanil plasebo’ mempunyai  
kejadian  kesan sampingan ubat tahan sakit yang lebih tinggi .  7 pesakit (25%) dalam 
Kumpulan ‘remifentanil plasebo’  dan 1 pesakit (3.7%) dalam Kumpulan ‘remifentanil + 
midazolam’ muntah  selepas operasi 
 
Kesimpulan : 
Ubat ‘remifentanil’  adalah berkesan dan dapat memberikan  keselesaan sepanjang operasi 
dijalankan dalam rawatan pengawasan anesthesia pada dos 1.57ng / ml apabila digunakan 
persendirian sahaja, atau pada  dos 0.92ng/ml apabila bercampur dengan ubat  
‘midazolam’. Oleh itu, menambahkan  ‘midazolam’ dengan ‘remifentanil’ boleh 
mengurangkan dos ‘remifentanil’ yang digunakan, dan  mnencapai masa yang lebih singkat 
untuk mendapatkan skor kurang sakit  yang dihendaki semasa pembedahan. Walau 
bagaimanapun, terdapat   peningkatan kejadian komplikasi ( penurunan nadi pernafasan , 
penurunan nadi jantung  dan penurunan tekanan darah) dalam Kumpulan ‘midazolam + 
remifentanil’  dan pada aspek yang lain,  terdapat peningkatan kejadian kesan sampingan  
ubat tahan sakit (loya, muntah dan  gatal ) dalam kumplan  ‘remifetanil placebo’ sahaja 
 
Kata kunci: rawatan pengawasan anesthesia, kegagalan buah pinggang peringkat akhir , 
pembedahan’ tenkchoff’,  ubat ‘midazolam’, ubat  ‘remifentanil’ , infusi sasaran dikawal ( 
TCI)  
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ABSTRACT 
 
TITLE: COMPARING THE EFFICACY AND REQUIREMENT OF  REMIFENTANIL 
INFUSION ALONE   VERSUS REMIFENTANIL INFUSION + MIDAZOLAM FOR 
END STAGE RENAL FAILURE ( ESRF) PATIENT DURING TENCKHOFF 
INSERTION  IN MONITORED ANAESTHESIA CARE ( MAC) 
 
Introduction:  
Remifentanil ,an ultra-short acting opioid analgesic, may be useful as an intravenous 
adjuvant to local anaesthetic  for treating patient discomfort and pain during monitored 
anesthesia care ( MAC). However , the remifentanil dose requirement , interaction with 
other commonly used sedative drug ( such as midazolam ), and the safety profile especially 
in ESRF patient for tenckhoff surgery have not been determined . Therefore  ,  this study 
was designed to define the appropriate dose of remifentanil hydrochloride alone or 
combined with midazolam , and at the same time to evaluate the safety and  efficacy of 
remifentanil during tenckhoff surgery MAC setting .  
 
Methods: 
58 patients scheduled for tenckhoff catheter insertion under MAC setting were recruited in 
this double‐blind study after approved by Research and Ethics Committee, school of 
Medical Sciences, University Sains Malaysia, Kelantan Health Campus. However, 3 
patients had drop off due to convert general anaesthesia.  Patients were randomly assigned 
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to one of two groups:  ( 1) remifentanil  TCI   starting  at 0.5ng/ml plasma concentration + 
placebo normal saline , ( 2)  remifentanil  TCI   starting  at 0.5ng/ml plasma concentration 
+ midazolam 0.02mg/kg  . Standard local anesthetic ( LA)  ( max dose  of 2 mg /kg  
levobupivacaine )  was allowed to be injected after that. Verbal assessments of pain, 
discomfort  and sedation according to modified OAA/S score  were assessed with 1st LA 
injection.  The level of pain ,  discomfort and sedation were subsequently assessed every 5 
minutes. Patient oxygen saturation, respiratory rate and heart rate were monitored at 5 
minutes interval. Remifentanil was titrated (in increments of 0.1ng/ml from the initial rate) 
to limit patient discomfort or pain intraoperatively and the infusion was terminated at the 
completion of skin closure. Post operatively, patient were assessed for incidence of opioid’s 
side effect  such as nausea , vomiting and pruritus   
Results:  
 At the time of the local anaesthetic, more patients in the remifentanil + placebo group 
experienced severe pain (78.6%) and severe discomfort ( 46.4%) as compared with 
midazolam + remifetanil group (  29.6% and 11.1%, respectively). The final mean  ±SD 
remifentanil TCI were 1.57 ± 0.11 ng/ml (remifentanil + placebo ) and 0.92 ± 0.11 ng/ml 
(remifentanil + midazolam). Midazolam + remifentanil group achieved pain score <4 in the 
faster time ( minutes) compared with  placebo group ( 9.78 vs 22.36 minutes  ; p < 0.05 )   
Generally,   Midazolam + remifentanil group patients had higher incidences of all adverse 
evenst intraoperatively. 7 patients (25.9%) in the remifentanil  + midazolam group and 2 
patients (7.1%) in the remifentanil  alone group experienced brief periods hypoventilation 
(< 8 breaths/min). On the other hand,  Remifetanil placebo group patient had higher 
incidence of post operative opioid side effects .  7 patients (25%) in the remifentanil  
  
 
xvii 
placebo group and 1 patients (3.7%) in the remifentanil  + midazolam group experienced 
vomiting . 
 
Conclusions 
TCI remifentanil provided effective analgesia and comfort during MAC at a mean plasma 
concentration 1.57ng/ml  when administered alone, or at a mean plasma concentration  of 
0.92ng/ml  in combination with  midazolam. Thus , the adding of midazolam in 
combination with TCI remifentanil  could reducing the dose  of TCI remifentanil used ,  
and faster time to achieve satisfactory  pain score during surgery. 
However, there were   increased  incidences of intraoperative adverse even    ( hypotension 
, bradycardia and respiratory depression ) with midazolam + remifentanil group   and on the 
other hand,    increase incidences of opiods side effecst ( nausea , vomiting , prutitus ) with 
remifentanil alone  . 
 
Keyword:  Monitored Anesthesia Care ,  End Stage Renal Failure , Tenkchoff Surgery , 
Midazolam  Remifentanil ,  Target Controlled Infusion 
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Chapter 1 INTRODUCTION 
ESRF  patient  often possess   high anesthesia risk even come for minor surgery due to their 
underlying co–morbidity such as hypertension ,  ischemic heart disease , diabetes mellitus  
and congestive heart failure with poor functional status,  electrolyte imbalance and impair 
kidney function.  This cause them have a higher risk of intraoperative cardiac event. 
 In addition, because of the alter drug metabolism due to impair renal function, most of the 
anesthetists are having difficulty in finding a balance between adequate dose of iv induction 
agent and systemic opioids to provide a good anesthesia and analgesic and at the same time 
avoiding the exaggerating of drug’s side effect which is common in this group of patient.  
Vigilance are utmost important when provide general anesthesia for this group of patient, 
yet this group of patient often presented unexpected general anesthesia complication that 
putting the anesthetist in the difficult situation.     
On the other hand, the most common operation done on ESRF patient are fistula creation , 
tenckhoff catheter insertion for the purpose of dialysis, and operation related to 
complication of underlying co-morbid illness.  These operation usually done under local 
anesthetics and sedation giving by surgeon, but are often result in inadequate pain and 
anxiety controlled which induce physiological stress  and dissatisfaction  among  ESRF 
patient .  
Thus,  monitored anesthesia care ( MAC )  is a good choice that suited all the parties ,  it 
can offer  a safe anesthesia to this group of patient  without the risk of general anesthesia , 
can improve patient satisfaction and provide a clam and pain free surgical field for the 
surgeon . 
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 However,  the type and dose of sedation and analgesic used especially  in ESRF patient is a 
continuously topic of research as it is determined by age,  cardiac function , underlying  co-
morbidity  and renal function. Thus, the challenge remained in avoiding the complication of 
sedative and analgesic agent but at the same time providing a conscious sedation with   the 
aim of  
1. Good pain control obtain by local anaesthetics and analgesic drugs    
2. Safe sedation with correct monitoring   
3.  Anxiety control and reduction of external stress during the operation   
 
Midazolam is a short-acting benzodiazepine that possesses anxiolytic, amnestic, hypnotic, 
anticonvulsant, skeletal muscle relaxant, and sedative properties. Midazolam has a fast 
recovery time and is the most commonly used benzodiazepine as a premedication for 
sedation, less commonly it is used for induction and maintenance of anesthesia. Sedation in 
adult is achieved within 3 to 5 minutes after intravenous (IV) injection. Titration to effect 
with multiple small doses is essential for safe administration.  
 
Although midazolam and fentanyl are widely used during MAC, their potent synergistic 
interaction can result in significant respiratory depression ( Bailey et al 1990) especially in 
renal impairment patient . Even though this synergistic effect is well known for midazolam 
and fentanyl, but there is  not  much data regarding  interaction between  midazolam and 
remifentanil, in view of the unique pharmacokinetic of remifentanil, which is much 
different from fentanyl.  
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The usage of remifentanil in the new era of anesthesia care is growing rapidly due to its 
unique features. Remifentanil is a potent ultra-short-acting synthetic opioid analgesic drug. 
It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic.   It 
has a rapid blood-brain equilibration half-time and a rapid onset of action. The 
pharmacodynamics effects of remifentanil closely follow the measured blood 
concentrations, allowing direct correlation between dose, blood levels, and response.  
 
Since the post-operative opioid analgesic effect may not be essential for procedure under 
MAC  because of residual LA effect , a rapid and ultra – short acting  opioids analgesic 
such as remifentanil could prove to be a valuable supplement to LA  in the intra operative  
management  of patient pain during MAC ( Rosow 1993  ) , which make it a good choice in  
ESRF patient . However, the side effect of opioids remain a concern and so far there are 
minimal data regarding the requirement and efficacy of remifentanil in ESRF patient 
undergoing MAC surgery. 
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Chapter 2: OBJECTIVE AND HYPOTHESIS  
 
General Objective 
 To compare the efficacy and requirement of remifentanil TCI alone versus remifentanil 
TCI + midazolam for ESRF patient dztedfgnuring tenckhoff surgery in MAC setting 
 
Specific Objective 
A) Primary Outcome  
1. To compare the effectiveness of remifentanil alone in terms of  time ( minutes ) to 
achieve  adequate analgesic during tenckhoff surgery MAC setting versus combination with  
midazolam   
 
2. To determine the target plasma concentration (ng/ml) of remifentanil alone and when 
combined with midazolam to achieve adequate analgesic during tenckhoff surgery MAC 
setting. 
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B ) Secondary Outcomes 
1. To evaluate the occurrence  of opioids side effects  ( nausea, pruritus, vomiting )  with 
remifentanil TCI with or without midazolam  
 
2. To correlate  the occurrence  of adverse events in term of hypotension ,  respiratory 
depression  and bradycardia with  remifentanil TCI  with or without midazolam    
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Research Hypothesis 
The combination of midazolam with TCI remifentanil can reduce the mean plasma 
concentration (ng/ml) of remifentanil requirement during tenkhoff surgery in ESRF patient 
in MAC setting 
 
Null Hypothesis  
There is no different in mean plasma concentration (ng/ml) between remifentanil TCI alone 
or remifentanil TCI  combined with midazolam during tenckhoff surgery  in ESRF patient 
in MAC setting 
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Chapter 3 LITERATURE REVIEW 
3.1 Midazolam  
3.1.1   Overview    
Midazolam is a short-acting benzodiazepine that possess anxiolytic, amnestic, hypnotic, 
anticonvulsant, skeletal muscle relaxant, and sedative properties. (Mandrioli et al 2008).   
Midazolam has a fast recovery time and is the most commonly used benzodiazepine as a 
premedication for sedation, less commonly it is used for induction and maintenance 
of anaesthesia (Stoelting 2006). 
Midazolam, like many other benzodiazepines, has a rapid onset of action, high 
effectiveness and low toxicity level. Drawbacks of midazolam include drug 
interactions, tolerance, and withdrawal syndrome, as well as adverse events including 
cognitive impairment and sedation. (Riss 2008).  Paradoxical effects occasionally can occur, 
including restless and delirium, most commonly in children and the elderly ( Riss 2008 ) , 
particularly after intravenous administration. 
Midazolam is characterized by a pH-dependent ring opening phenomenon in which the ring 
remains open at pH values of <4, thus maintaining the water solubility of the drug (Fig. 3.1). 
The ring closes at pH values of >4, as when the drug is exposed to physiologic pH, thus 
converting midazolam to a highly lipid-soluble drug (stoelting 2006), and this characteristic 
is responsible for the fast onset of action of midazolam as compare with others 
benzodiazepines.  
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Figure 3.1 Reversible ring opening of midazolam above and below at pH of 4 
( Mohler H, Richards JG. The benzodiazepine receptor: a pharmacologic control element of 
brain function. Eur J Anesthesiol Suppl 1988;2:15-24 ) 
 
3.1.2 Mechanism Of Action 
Midazolam produce all the pharmacologic effects by facilitating the actions of γ-
aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the CNS ( figure 
3.2) . Benzodiazepines do not activate GABA receptors but rather enhance the affinity of 
the receptors for GABA (Mohler H, Richards JG 1988 ). 
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Figure 3.2. Model of the γ-aminobutyric acid (GABA) receptor  
( Mohler H, Richards JG. The benzodiazepine receptor: a pharmacologic control element of 
brain function. Eur J Anesthesiol Suppl 1988;2:15-24 ) 
 
As a result of this drug-induced increased affinity of GABA receptors for the inhibitory 
neurotransmitter, an enhance opening of chloride gating channels results in increased 
chloride conductance, thus producing hyperpolarization of the postsynaptic cell membrane 
and rendering postsynaptic neurons more resistant to excitation ( stoelting 2006 ). 
 
 The GABA receptor is a large macromolecule that contains physically separate binding 
sites (principally α, β, and γ subunits) not only for GABA and the benzodiazepines but also 
for barbiturates, etomidate, propofol, neurosteroids, and alcohol ( stoelting 2006 ). 
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3.1.3 Pharmacokinetic Of Midazolam  
Midazolam undergoes rapid absorption from the gastrointestinal tract and achieves prompt 
passage across the blood-brain barrier. Despite this prompt passage into the brain, 
midazolam is considered to have a slow effect-site equilibration time (0.9 to 5.6 minutes) 
compared with other drugs such as propofol and thiopental. In this regard, intravenous 
doses of midazolam should be sufficiently spaced to permit the peak clinical effect to be 
appreciated before a repeat dose is considered ( stoelting 2006 ). 
 
Table 3.1 :  Comparative Pharmacology Of Benzodiazepines 
 Equivalent 
Dose     
 ( mg) 
Volume of 
Distribution  
( liter /kg) 
Protein 
binding     
(%) 
Clearance  
(mg/kg/min ) 
Elimination 
Half- time  
( hrs) 
Midazolam 0.15-0.3 1.0-1.5 96-98 6-8 1-4 
Diazepam 0.3-0.5 1.0-1.5 96-98 0.2-0.5 21-37 
Lorazepam 0.05 0.8-1.3 96-98 0.7-1.0 10-20 
 ( Stoelting, Robert K.; Hillier, Simon C.Pharmacology and Physiology in Anesthetic 
Practice, 2nd Edition 2006 Lippincott Williams & Wilkin)  
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Metabolism 
Midazolam is rapidly metabolized by hepatic and small intestine cytochrome P-450 
(CYP3A4) enzymes to active 1-hydroxymidazolam that may accumulate in 
critically ill patients and inactive metabolites. The metabolism of midazolam is 
slowed in the presence of drugs that inhibit cytochrome P-450 enzymes (cimetidine, 
erythromycin, calcium channel blockers, and antifungal drugs) and may result in 
unexpected CNS depression. Age related deficits, renal and liver status affect the 
pharmacokinetic factors of midazolam as well as its active metabolite (Spina et al 
2007). Thus, dose reduction should be consider when administrated midazolam to 
these group of patient.  However, the active metabolite of midazolam is minor and 
contributes to only 10 percent of biological activity of midazolam.  
 
Renal Clearance 
The elimination half-time, volume of distribution (Vd), and clearance of midazolam 
are not altered by renal failure.  Midazolam had an elimination half-life of one to 
four hours. However, in the elderly, as well as young children and adolescents, the 
elimination half-life is longer (Rosenbaum et al 2009)          
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 3.1.4 Pharmacodynamic Of Midazolam  
A .Central Nervous System 
Midazolam, like other benzodiazepines, produces decreases in cerebral metabolic 
oxygen requirements (CMRO2) and cerebral blood flow analogous to barbiturates 
and propofol. In contrast to these drugs, midazolam is unable to produce an 
isoelectric EEG, emphasizing that a ceiling effect exists with respect to the decrease 
in CMRO2 produced by increasing doses of midazolam 
Similar to thiopental, induction of anaesthesia with midazolam does not prevent 
increases in ICP associated with direct laryngoscopy for tracheal  intubation  
(stoelting 2006). Midazolam is also a potent anticonvulsant effective in the 
treatment of status epilepticus 
 
B.  Respiratory system  
Patients with chronic obstructive pulmonary disease experience a greater 
midazolam-induced depression of ventilation. Transient apnoea may occur after the 
rapid injection of large doses of midazolam, especially in the presence of 
preoperative medication that includes an opioid. Benzodiazepines also depress the 
swallowing reflex and decrease upper airway activity (stoelting 2006). 0.15 mg/kg 
of midazolam may cause respiratory depression, which is postulated to be a central 
nervous system (CNS) effect (Reves 1985). When midazolam is administered in 
combination with fentanyl, the incidence of hypoxemia or apnea becomes more 
likely (Bailey et al 1990 ) 
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C. Cardiovascular System 
In the presence of hypovolemia, the administration of midazolam results in 
enhanced blood pressure-lowering effects similar to those produced by other 
intravenous induction drugs. Midazolam does not prevent the blood pressure and 
heart rate responses evoked by intubation of the trachea. (stoelting 2006 )  
 
D. Antagonist  
Flumazenil, a benzodiazepine antagonist drug, can be used to treat an overdose of 
midazolam, as well as to reverse sedation (Olkkola 2008).  However, flumazenil can 
trigger seizures in mixed overdoses and in benzodiazepine-dependent individuals, 
so is not used in most cases. 
 
3.1.5   General Usage Of Midazolam  
A. Preoperative Medication 
Midazolam is the most commonly used oral preoperative medication. Oral 
midazolam at a dose of 0.25 mg/kg is effective for producing sedation and 
anxiolysis with minimal effects on ventilation and oxygen saturation. 
The anterograde amnesia property of midazolam is useful for premedication before 
surgery to inhibit unpleasant memories ( Riss 2008) 
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B. Intravenous Sedation 
Midazolam in doses of 1.0 to 2.5 mg IV is effective for sedation during regional 
anaesthesia, as well as for brief therapeutic procedures. Midazolam-induced 
depression of ventilation is exaggerated (synergistic effects) in the presence of 
opioids and other CNS depressant drugs (stoelting 2006). It is important to 
appreciate that increasing age greatly increases the pharmacodynamics sensitivity to 
the hypnotic effects of midazolam. Midazolam is also used for 
endoscopy procedural sedation ( McQuaid et al 2008)   and sedation in intensive 
care  (Brown  et al 2005 )  
 
C. Induction of Anaesthesia 
Anaesthesia can be induced by administration of midazolam, 0.1 to 0.2 mg/kg IV, 
over 30 to 60 seconds. Onset of unconsciousness (synergistic interaction) is 
facilitated when a small dose of opioid (fentanyl, 50 to 100 µg IV or its equivalent) 
precedes the injection of midazolam by 1 to 3 minutes.  
 
D. Maintenance of Anaesthesia 
Midazolam may be administered to supplement opioids, propofol, and/or inhaled 
anaesthetics during maintenance of anaesthesia. Anaesthetic requirements for 
volatile anaesthetics are decreased in a dose-dependent manner by midazolam 
(stoelting 2006).   
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E. Postoperative Sedation 
The long-term intravenous administration of midazolam (loading dose 0.5 to 4 mg 
and maintenance dose 1 to 7 mg/hr) to produce sedation in intubated patients results 
in the relative saturation of peripheral tissues with midazolam, and clearance from 
the systemic circulation becomes less dependent on redistribution into peripheral 
tissues and more dependent on hepatic metabolism. Emergence time from 
midazolam is increased in elderly patients, obese patients, and in the presence of 
severe liver disease. 
F. Seizure  
Administration of midazolam by the intranasal or the buccal route (absorption via 
the gums and cheek) as an alternative to rectally administered diazepam is 
becoming increasingly popular for the emergency treatment of seizures in children 
(Appleton et al 2008).    
However long-term use for the management of epilepsy is not recommended, due to 
the significant risk of tolerance (which renders midazolam and other 
benzodiazepines ineffective) and the significant side effect of sedation (Isojärvi 
1998) 
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3.1.6 Usage of Midazolam in   ESRF patient       
Caution is required in the renal impairment patient, as they are more sensitive to the 
pharmacological effects of benzodiazepines, metabolize them more slowly, and are more 
prone to adverse effects, including drowsiness, amnesia (especially anterograde 
amnesia), ataxia, and hangover effects ( Verbeeck   2008  )  
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3.2 Remifentanil   
3.2.1 Overview Of Opioids 
An opioid is any psychoactive chemical that resembles morphine or other opiates in its 
pharmacological effects. Opioids work by binding to opioid receptors, which are found 
principally in the central and peripheral nervous system and the gastrointestinal tract. The 
receptors in these organ systems mediate both the beneficial effects and the side effects of 
opioids. 
Opiods can be classify as  
• Natural opiates:  primarily morphine, codeine, and thebaine,   
• Semi-synthetic opioids: created from either the natural opiates or morphine esters, 
such as hydromorphone,  hydrocodone,  oxymorphone  and  buprenorphine 
• Fully synthetic opioids: such as  fentanyl, pethidine ,  methadone , tramadol and 
remifentanil  
There are also endogenous opioids that are   produced in the body include: 
• Endorphins 
• Enkephalins 
• Dynorphins 
• Endomorphins 
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β-endorphin is expressed in Pro-opiomelanocortin (POMC) cells in the arcuate nucleus, in 
the brainstem and in immune cells, and acts through μ-opioid receptors. β-endorphin has 
many effects, including on sexual behavior and appetite. β-endorphin is also secreted into 
the circulation from pituitary corticotropes and melanotropes. α-neo-endorphin is also 
expressed in POMC cells in the arcuate nucleus. (stoelting 2006 ) 
 
met-enkephalin is widely distributed in the CNS and in immune cells; [met]-enkephalin is a 
product  of  the  proenkephalingene,  and  acts  through  μ  and  δ-opioid receptors.           
leu-enkephalin also a product of the proenkephalin gene, acts through δ-opioid receptors. 
 
Dynorphin acts through κ-opioid receptors, and is widely distributed in the CNS, including 
in the spinal cord andhypothalamus, including in particular the arcuate nucleus and in 
both oxytocin and vasopressin neurons in the supraoptic nucleus. 
 
Endomorphin acts through μ-opioid receptors, and is more potent than other endogenous 
opioids at these receptors 
 
Opioid Receptors 
Opioid receptors are classified as µ, δ, and κ receptors. These opioid receptors belong to a 
superfamily of guanine (G) protein-coupled receptors. µ or morphine-preferring receptors 
are principally responsible for supraspinal and spinal analgesia. Naloxone is a specific µ 
receptor antagonist, attaching to but not activating the receptor. 
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Usage of Opioids  
Opioids have long been used to treat acute pain , such as post-operative pain (Alexander et 
al 2012). They have also been found to be invaluable in palliative care to alleviate the 
severe, chronic, disabling pain of terminal conditions such as cancer, and degenerative 
conditions such as rheumatoid arthritis. However, opioids should be used cautiously in 
chronic non-cancer pain (Okie 2010). High doses are not necessarily required to control the 
pain of advanced or end-stage disease. 
Tolerance (in which the body becomes less responsive to the same dosage of the drug) may 
occur. In spite of tolerance, the dose required to achieve analgesia can level off for many 
months at a time depending on severity of pain, which varies. Thus in many cases opioids 
are a successful long-term care strategy for those in chronic cancer pain. 
 
3.2.2 Overview Of Remifentanil 
Remifentanil is a congener of the fentanyl family of opioids that is approved for use as a 
supplement to general anaesthesia (and monitored anaesthesia care/acute pain management) 
by the United States Food and Drug Administration in 1996  (Egan TD 1996) . 
Remifentanil is structurally unique (Fig. 3.3)   because of its ester linkage, which renders it 
susceptible to hydrolysis to inactive metabolites by nonspecific plasma and tissue esterases. 
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Figure 3.3 structural of Remifentanil  
 (Stoelting, Robert K.; Hillier, Simon C. Pharmacology and Physiology in Anaesthetics 
Practice, 2nd Edition 2006 Lippincott Williams & Wilkin)  
 
This unique pathway of metabolism imparts to remifentanil 
 (a) Brevity of action, 
 (b) Precise and rapidly titratable effect due to its rapid onset (similar to that of alfentanil) 
and offset, 
 (c) Noncumulative effects, and 
 (d) Rapid recovery after discontinuation of its administration ( stoelting 2006 ) 
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3.2.3 Pharmacokinetic Of Remifentanil  
The rapid metabolism of remifentanil and its small Volume of distribution mean that 
remifentanil will accumulate less than other opioids (predictable termination of drug effect). 
The combination of rapid clearance and small Volume of distribution produces a drug with 
a uniquely evanescent effect. The peak effect-site concentration of remifentanil will be 
present within 1.1 minutes, compared with 1.4 minutes for alfentanil. (Ultiva 1998) 
 
A. Metabolism 
Remifentanil is unique among the opioids in undergoing metabolism to inactive 
metabolites by nonspecific plasma and tissue esterases. Remifentanil is metabolized 
to a compound (remifentanil acid) which has 1/4600 the potency of the parent 
compound (Hoke et al 1997  , Egan TD 1996). Remifentanil does not appear to be a 
substrate for butyrylcholinesterases (pseudocholinesterase), and thus its clearance 
should not be affected by cholinesterase deficiency or anticholinergics.  
 
B. Elimination Half-Time 
Unlike other opioids, remifentanil has a short elimination half‐life of 3–10 min, 
(Glass et al 1993) and the duration of action does not increase with increasing 
duration of administration because of rapid clearance and lack of drug accumulation 
 
C. Context-Sensitive Half-Time 
The context-sensitive half-time for remifentanil is independent of the duration of 
infusion and is estimated to be about 4 minutes ( Edan et al 1993 ) ( figure 3.4) . 
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Figure 3-4. Computer simulation-derived context-sensitive half-times (time necessary for 
the plasma concentration to decrease 50% after discontinuation of the infusion) as a 
function of the duration of the intravenous infusion. 
 (From Egan TD, Lemmens HJM, Fiset P, et al. The pharmacokinetics of the new short-
acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anaesthesiology 
1993;79:881-892; ) 
 
   
3.2.4 Pharmadynamic Of Remifentanil  
As a pure mu-agonist, remifentanil produces all the opioid effects characteristic of the 
fentanyl family of opioids (Egan TD 1996). Its therapeutic effects therefore include dose-
related analgesia and sedation.  In terms of potency, remifentanil is substantially more 
potent than alfentanil and slightly less potent than fentanyl  ( Edan et al 1996  ,Glass et al 
1999) 
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A. Cardiovascular Effects 
As  with morphine and fentanyl, remifentanil can result in hypotension  due to 
histamine release  (  Sebel et al  1995 ).Bradycardia can also  occur   and may lead 
to occasional decreases in blood pressure and cardiac output ( Dershwitz et al1995 )  
 
 
B. Respiratory effect  
Remifentanil produce a dose-dependent and gender-specific depression of 
ventilation, primarily through an agonist effect at µ2 receptors, which leads to a 
direct depressant effect on brainstem ventilation centers. (Bowdle et al 1996) 
 
Its depression of ventilation is characterized by decreased responsiveness of these 
ventilation centres to carbon dioxide, as reflected by an increase in the resting 
PaCo2 and displacement of the carbon dioxide response curve to the right.  
 
Advanced age and the occurrence of natural sleep increases the ventilatory 
depressant effects of opioids, whereas pain from surgical stimulation counteracts the 
ventilation depression produced. 
 
C. Nervous System 
In the absence of hypoventilation, opioids decrease cerebral blood flow and 
possibly intracranial pressure (ICP).  
  
 
24 
 
However, These drugs must be used with caution in patients with head injury 
because of their 
 (a) Associated effects on wakefulness, 
 (b) Production of miosis , and  
(c) Depression of ventilation with associated increases in ICP if the PaCo2 becomes 
increased.  
Skeletal muscle rigidity, especially of the thoracic and abdominal muscles, is 
common when large doses of remifentanil are administered rapidly intravenously. 
 
D. Nausea and Vomiting 
Nausea and vomiting induced by opioids reflects their direct stimulation of the 
chemoreceptor trigger zone in the floor of the fourth ventricle.  (patel  et al 1996  
edan et al 1993 ) 
 
In a study by Gold et al (1997 ) ,  almost half of the patient develop  side effect of opioids 
including nausea , vomiting , headache and pruritus when giving remifentanil infusion 
during conscious sedation ,  where else another study showed there were 16% of patient in 
remifentanil alone group develop respiratory depression with respiratory rate < 8 breath per 
min (Avramov et al 1996 ) 
 
 
